

TG THERAPEUTICS, INC.  
Form 8-K  
June 04, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 3, 2018

TG Therapeutics, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware 001-32639 36-3898269  
(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)  
of Incorporation)

2 Gansevoort Street, 9th Floor  
New York, New York 10014  
(Address of Principal Executive Offices)

(212) 554-4484  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).  
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 8.01. Other Events.

On June 4, 2018, TG Therapeutics, Inc. (the “Company”) issued a press release announcing updated clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy presented during the 54th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference. Filed as Exhibit 99.2 and incorporated in this Item by reference are slides utilized at the Company’s Investor and Analyst event on June 3, 2018.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated June 4, 2018.

99.2 Slides from Analyst and Investor Event, dated June 3, 2018.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: June 4, 2018

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer